|
Rating |
| 7900
Hyperthyroidism, including, but not limited to, Graves'
disease: |
|
| For six months
after initial diagnosis |
30 |
| Thereafter,
rate residuals of disease or complications of medical treatment
within the appropriate diagnostic code(s) within the appropriate
body system. |
|
| Note (1): If
hyperthyroid cardiovascular or cardiac disease is present,
separately evaluate under DC 7008 (hyperthyroid heart
disease). |
|
| Note (2):
Separately evaluate eye involvement occurring as a manifestation of
Graves' Disease as diplopia (DC 6090); impairment of central visual
acuity (DCs 6061-6066); or under the most appropriate DCs in §
4.79. |
|
| 7901 Thyroid
enlargement, toxic: |
|
| Note (1):
Evaluate symptoms of hyperthyroidism under DC 7900,
hyperthyroidism, including, but not limited to, Graves'
disease. |
|
| Note (2): If
disfigurement of the neck is present due to thyroid disease or
enlargement, separately evaluate under DC 7800 (burn scar(s) of the
head, face, or neck; scar(s) of the head, face, or neck due to
other causes; or other disfigurement of the head, face, or
neck). |
|
| 7902 Thyroid
enlargement, nontoxic: |
|
| Note (1):
Evaluate symptoms due to pressure on adjacent organs (such as the
trachea, larynx, or esophagus) under the appropriate diagnostic
code(s) within the appropriate body system. |
|
| Note (2): If
disfigurement of the neck is present due to thyroid disease or
enlargement, separately evaluate under DC 7800 (burn scar(s) of the
head, face, or neck; scar(s) of the head, face, or neck due to
other causes; or other disfigurement of the head, face, or
neck). |
|
| 7903
Hypothyroidism: |
|
| Hypothyroidism
manifesting as myxedema (cold intolerance, muscular weakness,
cardiovascular involvement (including, but not limited to
hypotension, bradycardia, and pericardial effusion), and mental
disturbance (including, but not limited to dementia, slowing of
thought and depression)) |
100 |
| Note (1): This
evaluation shall continue for six months beyond the date that an
examining physician has determined crisis stabilization.
Thereafter, the residual effects of hypothyroidism shall be rated
under the appropriate diagnostic code(s) within the appropriate
body system(s) (e.g., eye, digestive, and mental disorders). |
|
| Hypothyroidism
without myxedema |
30 |
| Note (2): This
evaluation shall continue for six months after initial diagnosis.
Thereafter, rate residuals of disease or medical treatment under
the most appropriate diagnostic code(s) under the appropriate body
system (e.g., eye, digestive, mental disorders). |
|
| Note (3): If
eye involvement, such as exophthalmos, corneal ulcer, blurred
vision, or diplopia, is also present due to thyroid disease, also
separately evaluate under the appropriate diagnostic code(s) in §
4.79, Schedule of Ratings - Eye (such as diplopia (DC 6090) or
impairment of central visual acuity (DCs 6061-6066)). |
|
| 7904
Hyperparathyroidism: |
|
| For six months
from date of discharge following surgery |
100 |
| Note (1): After
six months, rate on residuals under the appropriate diagnostic
code(s) within the appropriate body system(s) based on a VA
examination. |
|
| Hypercalcemia
(indicated by at least one of the following: Total Ca greater than
12 mg/dL (3-3.5 mmol/L), Ionized Ca greater than 5.6 mg/dL (2-2.5
mmol/L), creatinine clearance less than 60 mL/min, bone mineral
density T-score less than 2.5 SD (below mean) at any site or
previous fragility fracture) |
60 |
| Note (2): Where
surgical intervention is indicated, this evaluation shall continue
until the day of surgery, at which time the provisions pertaining
to a 100-percent evaluation shall apply. |
|
| Note (3): Where
surgical intervention is not indicated, this evaluation shall
continue for six months after pharmacologic treatment begins. After
six months, rate on residuals under the appropriate diagnostic
code(s) within the appropriate body system(s) based on a VA
examination. |
|
| Symptoms such
as fatigue, anorexia, nausea, or constipation that occur despite
surgery; or in individuals who are not candidates for surgery but
require continuous medication for control |
10 |
|
Asymptomatic |
0 |
| Note (4):
Following surgery or other treatment, evaluate chronic residuals,
such as nephrolithiasis (kidney stones), decreased renal function,
fractures, vision problems, and cardiovascular complications, under
the appropriate diagnostic codes. |
|
| 7905
Hypoparathyroidism: |
|
| For three
months after initial diagnosis |
100 |
| Thereafter,
evaluate chronic residuals, such as nephrolithiasis (kidney
stones), cataracts, decreased renal function, and congestive heart
failure under the appropriate diagnostic codes. |
|
| 7906
Thyroiditis: |
|
| With normal
thyroid function (euthyroid) |
0 |
| Note:
Manifesting as hyperthyroidism, evaluate as hyperthyroidism,
including, but not limited to, Graves' disease (DC 7900);
manifesting as hypothyroidism, evaluate as hypothyroidism (DC
7903). |
|
| 7907 Cushing's
syndrome: |
|
| As active,
progressive disease, including areas of osteoporosis, hypertension,
and proximal upper and lower extremity muscle wasting that results
in inability to rise from squatting position, climb stairs, rise
from a deep chair without assistance, or raise arms |
100 |
| Proximal upper
or lower extremity muscle wasting that results in inability to rise
from squatting position, climb stairs, rise from a deep chair
without assistance, or raise arms |
60 |
| With striae,
obesity, moon face, glucose intolerance, and vascular
fragility |
30 |
| Note: The
evaluations specifically indicated under this diagnostic code shall
continue for six months following initial diagnosis. After six
months, rate on residuals under the appropriate diagnostic code(s)
within the appropriate body system(s). |
|
| 7908
Acromegaly: |
|
| Evidence of
increased intracranial pressure (such as visual field defect),
arthropathy, glucose intolerance, and either hypertension or
cardiomegaly |
100 |
| Arthropathy,
glucose intolerance, and hypertension |
60 |
| Enlargement of
acral parts or overgrowth of long bones |
30 |
| 7909 Diabetes
insipidus: |
|
| For three
months after initial diagnosis |
30 |
| Note:
Thereafter, if diabetes insipidus has subsided, rate residuals
under the appropriate diagnostic code(s) within the appropriate
body system. |
|
| With persistent
polyuria or requiring continuous hormonal therapy |
10 |
| 7911 Addison's
disease (adrenocortical insufficiency): |
|
| Four or more
crises during the past year |
60 |
| Three crises
during the past year, or; five or more episodes during the past
year |
40 |
| One or two
crises during the past year, or; two to four episodes during the
past year, or; weakness and fatigability, or; corticosteroid
therapy required for control |
20 |
| Note (1): An
Addisonian “crisis” consists of the rapid onset of peripheral
vascular collapse (with acute hypotension and shock), with findings
that may include: anorexia; nausea; vomiting; dehydration; profound
weakness; pain in abdomen, legs, and back; fever; apathy, and
depressed mentation with possible progression to coma, renal
shutdown, and death. |
|
| Note (2): An
Addisonian “episode,” for VA purposes, is a less acute and less
severe event than an Addisonian crisis and may consist of anorexia,
nausea, vomiting, diarrhea, dehydration, weakness, malaise,
orthostatic hypotension, or hypoglycemia, but no peripheral
vascular collapse. |
|
| Note (3):
Tuberculous Addison's disease will be evaluated as active or
inactive tuberculosis. If inactive, these evaluations are not to be
combined with the graduated ratings of 50 percent or 30 percent for
non-pulmonary tuberculosis specified under § 4.88b. Assign the
higher rating. |
|
| 7912 Polyglandular
syndrome (multiple endocrine neoplasia, autoimmune polyglandular
syndrome): |
|
| Evaluate
according to major manifestations to include, but not limited to,
Type I diabetes mellitus, hyperthyroidism, hypothyroidism,
hypoparathyroidism, or Addison's disease. |
|
| 7913 Diabetes
mellitus: |
|
| Requiring more
than one daily injection of insulin, restricted diet, and
regulation of activities (avoidance of strenuous occupational and
recreational activities) with episodes of ketoacidosis or
hypoglycemic reactions requiring at least three hospitalizations
per year or weekly visits to a diabetic care provider, plus either
progressive loss of weight and strength or complications that would
be compensable if separately evaluated |
100 |
| Requiring one
or more daily injection of insulin, restricted diet, and regulation
of activities with episodes of ketoacidosis or hypoglycemic
reactions requiring one or two hospitalizations per year or twice a
month visits to a diabetic care provider, plus complications that
would not be compensable if separately evaluated |
60 |
| Requiring one
or more daily injection of insulin, restricted diet, and regulation
of activities |
40 |
| Requiring one
or more daily injection of insulin and restricted diet, or; oral
hypoglycemic agent and restricted diet |
20 |
| Manageable by
restricted diet only |
10 |
| Note (1):
Evaluate compensable complications of diabetes separately unless
they are part of the criteria used to support a 100-percent
evaluation. Noncompensable complications are considered part of the
diabetic process under DC 7913. |
|
| Note (2): When
diabetes mellitus has been conclusively diagnosed, do not request a
glucose tolerance test solely for rating purposes. |
|
| 7914 Neoplasm,
malignant, any specified part of the endocrine system |
100 |
| Note: A rating
of 100 percent shall continue beyond the cessation of any surgical,
X-ray, antineoplastic chemotherapy or other therapeutic procedure.
Six months after discontinuance of such treatment, the appropriate
disability rating shall be determined by mandatory VA examination.
Any change in evaluation based upon that or any subsequent
examination shall be subject to the provisions of § 3.105(e) of
this chapter. If there has been no local recurrence or metastasis,
rate on residuals. |
|
| 7915 Neoplasm,
benign, any specified part of the endocrine system: |
|
| Rate as
residuals of endocrine dysfunction. |
|
| 7916
Hyperpituitarism (prolactin secreting pituitary dysfunction): |
|
| Note: Evaluate
as malignant or benign neoplasm, as appropriate. |
|
| 7917
Hyperaldosteronism (benign or malignant): |
|
| Note: Evaluate
as malignant or benign neoplasm, as appropriate. |
|
| 7918
Pheochromocytoma (benign or malignant): |
|
| Note: Evaluate
as malignant or benign neoplasm as appropriate. |
|
| 7919 C-cell
hyperplasia of the thyroid: |
|
| If
antineoplastic therapy is required, evaluate as a malignant
neoplasm under DC 7914. If a prophylactic thyroidectomy is
performed (based upon genetic testing) and antineoplastic therapy
is not required, evaluate as hypothyroidism under DC 7903. |
|